Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Inhibitory serpins. New insights into their folding, polymerization, regulation and clearance.

Gettins PG, Olson ST.

Biochem J. 2016 Aug 1;473(15):2273-93. doi: 10.1042/BCJ20160014. Review.

2.
3.

Saturation Mutagenesis of the Antithrombin Reactive Center Loop P14 Residue Supports a Three-step Mechanism of Heparin Allosteric Activation Involving Intermediate and Fully Activated States.

Roth R, Swanson R, Izaguirre G, Bock SC, Gettins PG, Olson ST.

J Biol Chem. 2015 Nov 20;290(47):28020-36. doi: 10.1074/jbc.M115.678839. Epub 2015 Sep 10.

4.

Pigment epithelium-derived factor as a multifunctional regulator of wound healing.

Wietecha MS, Król MJ, Michalczyk ER, Chen L, Gettins PG, DiPietro LA.

Am J Physiol Heart Circ Physiol. 2015 Sep;309(5):H812-26. doi: 10.1152/ajpheart.00153.2015. Epub 2015 Jul 10.

5.

Conformational activation of antithrombin by heparin involves an altered exosite interaction with protease.

Izaguirre G, Aguila S, Qi L, Swanson R, Roth R, Rezaie AR, Gettins PG, Olson ST.

J Biol Chem. 2014 Dec 5;289(49):34049-64. doi: 10.1074/jbc.M114.611707. Epub 2014 Oct 20.

6.

The allosteric mechanism of activation of antithrombin as an inhibitor of factor IXa and factor Xa: heparin-independent full activation through mutations adjacent to helix D.

Dementiev A, Swanson R, Roth R, Isetti G, Izaguirre G, Olson ST, Gettins PG.

J Biol Chem. 2013 Nov 22;288(47):33611-9. doi: 10.1074/jbc.M113.510727. Epub 2013 Sep 25.

7.

Kinetic intermediates en route to the final serpin-protease complex: studies of complexes of α1-protease inhibitor with trypsin.

Maddur AA, Swanson R, Izaguirre G, Gettins PG, Olson ST.

J Biol Chem. 2013 Nov 1;288(44):32020-35. doi: 10.1074/jbc.M113.510990. Epub 2013 Sep 18.

8.
9.

How the serpin α1-proteinase inhibitor folds.

Dolmer K, Gettins PG.

J Biol Chem. 2012 Apr 6;287(15):12425-32. doi: 10.1074/jbc.M111.315465. Epub 2012 Feb 13.

11.

Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability.

Jensen JK, Thompson LC, Bucci JC, Nissen P, Gettins PG, Peterson CB, Andreasen PA, Morth JP.

J Biol Chem. 2011 Aug 26;286(34):29709-17. doi: 10.1074/jbc.M111.236554. Epub 2011 Jun 21.

12.

Regulation of proteases by protein inhibitors of the serpin superfamily.

Olson ST, Gettins PG.

Prog Mol Biol Transl Sci. 2011;99:185-240. doi: 10.1016/B978-0-12-385504-6.00005-1. Review.

PMID:
21238937
13.

Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors.

Olson ST, Richard B, Izaguirre G, Schedin-Weiss S, Gettins PG.

Biochimie. 2010 Nov;92(11):1587-96. doi: 10.1016/j.biochi.2010.05.011. Epub 2010 Jun 2. Review.

14.

Basis for the specificity and activation of the serpin protein Z-dependent proteinase inhibitor (ZPI) as an inhibitor of membrane-associated factor Xa.

Huang X, Dementiev A, Olson ST, Gettins PG.

J Biol Chem. 2010 Jun 25;285(26):20399-409. doi: 10.1074/jbc.M110.112748. Epub 2010 Apr 28.

15.

Activation of antithrombin as a factor IXa and Xa inhibitor involves mitigation of repression rather than positive enhancement.

Gettins PG, Olson ST.

FEBS Lett. 2009 Nov 3;583(21):3397-400. doi: 10.1016/j.febslet.2009.10.005. Epub 2009 Oct 9.

16.
17.

Exosite determinants of serpin specificity.

Gettins PG, Olson ST.

J Biol Chem. 2009 Jul 31;284(31):20441-5. doi: 10.1074/jbc.R800064200. Epub 2009 Apr 28. Review.

19.
20.

alpha-Macroglobulins are present in some gram-negative bacteria: characterization of the alpha2-macroglobulin from Escherichia coli.

Doan N, Gettins PG.

J Biol Chem. 2008 Oct 17;283(42):28747-56. doi: 10.1074/jbc.M803127200. Epub 2008 Aug 12.

21.

Characterization of the conformational alterations, reduced anticoagulant activity, and enhanced antiangiogenic activity of prelatent antithrombin.

Richard B, Swanson R, Schedin-Weiss S, Ramirez B, Izaguirre G, Gettins PG, Olson ST.

J Biol Chem. 2008 May 23;283(21):14417-29. doi: 10.1074/jbc.M710327200. Epub 2008 Mar 28.

23.

Maspin binds to urokinase-type and tissue-type plasminogen activator through exosite-exosite interactions.

Al-Ayyoubi M, Schwartz BS, Gettins PG.

J Biol Chem. 2007 Jul 6;282(27):19502-9. Epub 2007 May 16.

25.

Cytokine response modifier a inhibition of initiator caspases results in covalent complex formation and dissociation of the caspase tetramer.

Dobó J, Swanson R, Salvesen GS, Olson ST, Gettins PG.

J Biol Chem. 2006 Dec 15;281(50):38781-90. Epub 2006 Oct 19.

27.

Dissection of RAP-LRP interactions: binding of RAP and RAP fragments to complement-like repeats 7 and 8 from ligand binding cluster II of LRP.

Lazic A, Dolmer K, Strickland DK, Gettins PG.

Arch Biochem Biophys. 2006 Jun 15;450(2):167-75. Epub 2006 May 5.

PMID:
16723114
29.

Lack of involvement of strand s1'A of the viral serpin CrmA in anti-apoptotic or caspase-inhibitory functions.

Simonovic M, Denault JB, Salvesen GS, Volz K, Gettins PG.

Arch Biochem Biophys. 2005 Aug 1;440(1):1-9.

PMID:
15993378
30.

Specificity and reactive loop length requirements for crmA inhibition of serine proteases.

Tesch LD, Raghavendra MP, Bedsted-Faarvang T, Gettins PG, Olson ST.

Protein Sci. 2005 Feb;14(2):533-42. Epub 2005 Jan 4.

31.

Crystal structure of human maspin, a serpin with antitumor properties: reactive center loop of maspin is exposed but constrained.

Al-Ayyoubi M, Gettins PG, Volz K.

J Biol Chem. 2004 Dec 31;279(53):55540-4. Epub 2004 Oct 22.

32.

The ternary complex of antithrombin-anhydrothrombin-heparin reveals the basis of inhibitor specificity.

Dementiev A, Petitou M, Herbert JM, Gettins PG.

Nat Struct Mol Biol. 2004 Sep;11(9):863-7. Epub 2004 Aug 15.

PMID:
15311268
33.

Use of NMR to study serpin function.

Gettins PG, Backovic M, Peterson FC.

Methods. 2004 Feb;32(2):120-9.

PMID:
14698624
34.
35.

Structural organization of the receptor associated protein.

Lazic A, Dolmer K, Strickland DK, Gettins PG.

Biochemistry. 2003 Dec 23;42(50):14913-20.

PMID:
14674767
37.

Canonical inhibitor-like interactions explain reactivity of alpha1-proteinase inhibitor Pittsburgh and antithrombin with proteinases.

Dementiev A, Simonovic M, Volz K, Gettins PG.

J Biol Chem. 2003 Sep 26;278(39):37881-7. Epub 2003 Jul 14.

40.

Pigment epithelium-derived factor (PEDF), a serpin with potent anti-angiogenic and neurite outgrowth-promoting properties.

Gettins PG, Simonovic M, Volz K.

Biol Chem. 2002 Nov;383(11):1677-82. Review.

PMID:
12530532
41.

Serpin structure, mechanism, and function.

Gettins PG.

Chem Rev. 2002 Dec;102(12):4751-804. Review. No abstract available.

PMID:
12475206
42.

Characterization of the LDL-A module mutants of Tva, the subgroup A Rous sarcoma virus receptor, and the implications in protein folding.

Wang QY, Manicassamy B, Yu X, Dolmer K, Gettins PG, Rong L.

Protein Sci. 2002 Nov;11(11):2596-605.

43.
45.

Importance of lysine 125 for heparin binding and activation of antithrombin.

Schedin-Weiss S, Desai UR, Bock SC, Gettins PG, Olson ST, Björk I.

Biochemistry. 2002 Apr 16;41(15):4779-88.

PMID:
11939772
46.

Insight into Residues Critical for Antithrombin Function from an Expanded Database of Sequences That Includes Frog, Turtle and Ostrich Antithrombins.

Backovic M, Gettins PGW.

ScientificWorldJournal. 2002 Mar 8;2:112-114. doi: 10.1100/tsw.2002.53. eCollection 2002. No abstract available.

47.

Solution structure of the viral receptor domain of Tva and its implications in viral entry.

Wang QY, Huang W, Dolmer K, Gettins PG, Rong L.

J Virol. 2002 Mar;76(6):2848-56.

48.

Helix D elongation and allosteric activation of antithrombin.

Belzar KJ, Zhou A, Carrell RW, Gettins PG, Huntington JA.

J Biol Chem. 2002 Mar 8;277(10):8551-8. Epub 2001 Dec 10.

49.
50.

Crystal structure of human PEDF, a potent anti-angiogenic and neurite growth-promoting factor.

Simonovic M, Gettins PG, Volz K.

Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11131-5. Epub 2001 Sep 18.

Supplemental Content

Loading ...
Support Center